Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
Pullan
P T
PT
D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use; D000077465:Cabergoline; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004873:Ergolines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006349:Heart Valve Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy*; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide / Q000009:adverse effects; D011388:Prolactin / Q000037:antagonists & inhibitors; D058826:Serotonin 5-HT2 Receptor Agonists; D014463:Ultrasonography
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D004873:Ergolines; D058826:Serotonin 5-HT2 Receptor Agonists; D010479:Pergolide; D001971:Bromocriptine; D011388:Prolactin; D000077465:Cabergoline